Schedule 13G ownership disclosure

Lyell Immunopharma Inc

Common Stock, par value $0.0001 · CUSIP: 55083R203

Event date: 2025-11-06

Filing-level shares
1,900,000
Percent of class
9.8%
  • Innovative Cellular Therapeutics Holdings Ltd

    Shares: 1,900,000 · Class: 9.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001140361-25-042006
Form type
SCHEDULE 13G
Filer
Innovative Cellular Therapeutics Holdings Ltd
CIK
CIK 2095697
Filed
Nov 13, 2025
Reporting period
Nov 06, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub